DOCSLIB.ORG

T Cell Maturation

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
T Cell Maturation T-cell Maturation T cell maturation What allows T cell maturation? T cell progenitor DN DP SP 2ry • Direct contact with thymic epithelial cells (Subcapsular (Cortex) (Medulla) lymphoid zone) organs • Influence of thymic hormones THYMUS • Growth factors (cytokines, CSF) The earliest T cell precursors in the thymus : Time Course of Appearance in Thymus - Express Thy-1 (mice) - Have not yet rearranged TCR loci - Do NOT express CD4 or CD8 - Are called “double negatives” MARKERS: - C-KIT - Receptor for Stem Cell Growth Factor - CD44 - Adh. Molecule. Homing to thymus - CD25 - Alpha chain of IL-2 receptor Double Negative Humans = 8-9 weeks - Most double negative thymocytes will give rise to αβαβαβ T cells (in mice and humans). - Some will differentiate into γδγδγδ T cells. - The developmental pathway of γδγδγδ T cells is not well defined. 1 Why is Pre-TCR important? -Double negative thymocytes first express Pre- Tα (surrogate chain) -They then undergo β chain locus re-arrangement . - Once a β chain is produced, a pre-TCR is expressed - Early markers are NOT expressed at this stage 1) Made productive TCR β chain re-arrangement 2) Signals for proliferation (similar β chain) and maturation 3) Suppresses further β chain re-arrangement (allelic exclusion) 4) Signals for TCR ααα chain to undergo re-arrangement 4) Induces development to CD4+8+ (double positive) stage Cells undergo positive and negative selection . Those that fail either selection - Following proliferation, α- chain locus undergo apoptosis. rearrangement occurs. DOUBLE POSITIVE STAGE If a productive rearrangement is made, an α/β TCR is expressed on the cell surface. Those that pass the selection step lose EITHER CD4 or CD8 becoming “single positives” These mature single positive cells leave the thymus. Kuby Figure 10-1 1111 Positive and Negative Selection of T cells: Summary: - Positive selection: occurs in the cortex and allows only those T cells that are able to bind to self-MHC molecules in the thymus to mature Positive selection results in self MHC restriction . - Negative selection: occurs in the medulla and removes T cells whose TCR strongly recognize (high affinity) self-MHC (or self self-peptides plus self MHC). Die of apoptosis within the thymus. Negative selection results in self-tolerance (to some extent). MHC Restriction Self Tolerance POSITIVE NEGATIVE 2 Model to Explain CD4/CD8 Single Positive Cells T cell maturation T cell progenitor DN DP SP 2ry (Subcapsular (Cortex) (Medulla) lymphoid Double zone) organs Positive THYMUS - Thy-1, CD44, c-Kit, CD25 - CD3 - TCR β-chain - Positive and Negative selection - Pre-Tααα - TCR ααα-chain - CD4 - AVIDITY HYPOTHESIS: Multiple interactions between TCR, CD8 - CD8 or CD4 with MHC-I or MHC-II will deliver the “right signal” (strength?) to thymocytes and instructs them to differentiate. You have to assume that signals are different for CD4 and CD8 T cells! Model to Explain CD4/CD8 Single Positive Cells Summary of T cell maturation ( αβαβαβ T cells only) - Thymocytes enter the thymus as "double negative“ (markers?) CD8 - β-chain rearrangement (apoptosis of cells that fail to rearrange βββ chain correctly) - pre-Tααα - surrogate α chain (pre-TCR) critical step will multiple roles - Proliferation of similar β-chain clones with surrogate ααα-chain - α-chain rearrangement (apoptosis of cells that fail to rearrange ααα chain correctly) CD4 - Expression of mature αβαβαβ TCR - Positive and negative selection (death of cells with too low or too high affinity for self MHC…>99% of thymocytes die within the thymus) - Expression of CD4 and CD8 (to form " double positive " thymocytes) - Expression of CD4 or CD8 is switched off randomly - Loss of either CD4 or CD8 - Only thymocytes with ON co-receptor and correct peptide+ MHC complex will mature - Migration to periphery of cells that successfully complete these steps Activation 3 1 CD45 CD45 2 2 Lck Fyn 4 4 ZAP-70 ITAMs 5 3 Signals through the TCR, CD3 and CD4/8 Signals through the TCR, CD3 and CD4/8 activate a protein tyrosine kinase (PTK) cascade activate a PTK cascade - PTK = enzyme that phosphorylates the amino acid tyrosine (Y) in ITAMs - CD4/8 are associated with a cytoplasmic tyrosine kinase enzyme – Lck (lymphocyte kinase) - PHOSPHATASES = enzymes that remove inhibitory phosphates 1.- TCR-MHC-Peptide activates the phosphathase CD45 2.- CD45 activates Fyn and Lck 3.- Activated Fyn and Lck phosphorylate ITAMs in CD3 chains 4.- Phosphorylated ITAM motifs on the CD3zz chains become a docking site for the PTK ZAP- 70 . 5.- Binding of CD4 to MHC allows Lck to phosphorylate and activate ZAP-70 to become an active PTK. Figure 9.5 - Activation of ZAP-70 initiates a cascade of events that The calcium: results in LAT activation and phosphorylation (activation) of phospholypase C (PLC γγγ1). 3. and PKC activate IkB kinase (IKK), which phosphorylates IkB, releasing the transcription factor NF-kB – which translocates to the nucleus. - PLC γγγ1 converts phosphatidyl inositol 4,5-biphosphate (PIP 2) to diacylglycerol ( DAG) and inositol 1,4,5-triphosphate 4. acts together with calmodulin to activate calcineurin (phosphatase) (IP 3): 4. Calcineurin activates the cytoplasmic component of the PLC γγγ1 transcription factor NFAT (NFAT c), causing it to translocate to PIP 2 DAG and IP 3 the nucleus, where it combines with NFAT n - IP 3 triggers the release of calcium from intracellular storage vesicles into the cytosol, thus raising cytoplasmic calcium levels. TRANSCRIPTION FACTORS- lead to gene transcription, cell The calcium : proliferation and differentiation. 1) synergizes with DAG to activate protein kinase C (PKC) 2) PKC activates the transcription factor NF-κB ZAP-70 also phosphorylates and activates LAT and SLP-76 1 - SLP-76 binds and activates PLC-γ, GEF and Tec Kinases - GEF activates the Ras pathway resulting in formation of the 4 Jun/Fos, a component of the AP-1 transcription factor. 2 3 - NFAT n and Jun/Fos bind to sites in the regulatory region of the IL-2 gene and increase transcription of IL-2. 5 - The expression of >70 genes is increased within 4 hr of T cell activation. - The potent immunosuppressive drugs cyclosporin and FK506 act by inhibiting the activation of calcineurin X NF-AT! ADAPTOR PROTEINS - SLP76 (SH 2-domain containing leukocyte protein of 76 KDa and LAT (Linker of activated T cells). ADAPTOR PROTEINS : 1) Serve as links for proteins, 2) Promote assembly of membrane proteins 4 The interaction of CD28 with B7 sends Expressed in resting and activated T cells additional activation signals . • CTLA-4 is not initially expressed, but is expressed after T cell activation. • CTLA-4 has a higher affinity for B7 than CD28 . Signal 2 • Interaction of CTLA-4 with B7 is thought to down- regulate T cell activation. • There are actually two related molecules: B7.1 and B7.2 Expressed after T cell activation Superantigens Super Antigens • Proteins produced by pathogens • Not processed by antigen presenting cells • Intact protein binds to the β variable region on TCR of T cells and to MHC class II on antigen presenting cells (APC) • Large numbers of activated T cells and APC release cytokines having pathological effects Consequences: • Because they cross-link the V β domain of the TCR with the V α domain of the MHC-II, this results in non-specific proliferation and activation. • Over production of Th cytokine leading to systemic toxicity (IFN-γ, TNF-α) and inflammatory mediators. • Deletion (negative selection) of thymocytes bearing V β domains recognized by the super antigen---- beneficial? 5 CLONAL EXPANSION vs CLONAL ANERGY = inability of T cell CLONAL EXPANSION vs CLONAL ANERGY = inability of T cell to respond after TCR-MHC/peptide stimulation to respond after TCR-MHC/peptide stimulation Signal 1 only Signal 1 only No Signal 2 Blockade of signal 2 ANERGY!!!! ANERGY!!!! CLONAL EXPANSION vs CLONAL ANERGY = inability of T cell CLONAL EXPANSION vs CLONAL ANERGY = inability of T cell to respond after TCR-MHC/peptide stimulation to respond after TCR-MHC/peptide stimulation Signal 1 Signal 1 Signal 2 Signal 2 CLONAL EXPANSION!!!! CLONAL EXPANSION!!!! During activation of helper T cells by antigen T cell differentiation: presenting cells, many cell-cell interactions must occur. • Remember: Naïve T cells continually re-circulate - Signal 1 is the interaction of the TCR with peptide antigen presented between the blood and lymph system search for on class II MHC (and interaction of CD4 with class II MHC). appropriate antigen - Signal 2 is the interaction is between CD28 (and CTLA-4) on the • Once activated (Remember signal 1 and 2) Primary helper T cell and B7 on the antigen-presenting cell. This provides a response where T cells proliferate and differentiate costimulatory activation signal. into effector and memory T cells. - If T cells receive signal 1 only, they will NOT be activated by antigen. • CD4 effector T cells can form two subpopulations Instead, they will become anergic i.e. they will become refractory to any based on cytokine production: TH1 subset (IL-2, IFN- subsequent activation by antigen . γ) and TH2 subset (IL-4, IL-5, IL-10) - If T cells receive signal 1 and signal 2, they will be activated to participate in an immune response to the antigen. • TH1: associated with cell-mediated functions inflammation (delayed-type hypersensitivity, (If T cells receive signal 2 only, nothing happens.) activation of CD8 T cells); TH2: associated with B- cell activation. 6 Th0 - Outcome of CD4 T cells Signal 1 - Th 0 will give rise to at least 3 Th populations Signal 2 - Th populations differentiated based on cytokine production ↑IL-2R ↑IL-2 Clonal expansion Why are DC better APCs? Suppressor T cells • The old questions revisited! • First described in the 70’s made CD8 + the candidate for Ts cells • Now it is believed that Ts cells are CD4 + cells with the phenotype CD4 +CD25 +.
Load more

Recommended publications
  • Our Immune System (Children's Book)
    OurOur ImmuneImmune SystemSystem A story for children with primary immunodeficiency diseases Written by IMMUNE DEFICIENCY Sara LeBien FOUNDATION A note from the author The purpose of this book is to help young children who are immune deficient to better understand their immune system. What is a “B-cell,” a “T-cell,” an “immunoglobulin” or “IgG”? They hear doctors use these words, but what do they mean? With cheerful illustrations, Our Immune System explains how a normal immune system works and what treatments may be necessary when the system is deficient. In this second edition, a description of a new treatment has been included. I hope this book will enable these children and their families to explore together the immune system, and that it will help alleviate any confusion or fears they may have. Sara LeBien This book contains general medical information which cannot be applied safely to any individual case. Medical knowledge and practice can change rapidly. Therefore, this book should not be used as a substitute for professional medical advice. SECOND EDITION COPYRIGHT 1990, 2007 IMMUNE DEFICIENCY FOUNDATION Copyright 2007 by Immune Deficiency Foundation, USA. Readers may redistribute this article to other individuals for non-commercial use, provided that the text, html codes, and this notice remain intact and unaltered in any way. Our Immune System may not be resold, reprinted or redistributed for compensation of any kind without prior written permission from Immune Deficiency Foundation. If you have any questions about permission, please contact: Immune Deficiency Foundation, 40 West Chesapeake Avenue, Suite 308, Towson, MD 21204, USA; or by telephone at 1-800-296-4433.
    [Show full text]
  • MCB 50 Immunity and Disease Lecture Outline MHC Restriction Jan
    MCB 50 Immunity and Disease Lecture Outline MHC Restriction Jan. 31, 2001 I. Definition of self MHC restriction; MHC restriction is the requirement that APC or target cells express MHC molecules that the T cell recognizes as self in order for T cell to respond to the antigen presented by that APC or target cell. (T cells will only recognize antigens presented by their own MHC molecules.) CD8 T cells bind class I MHC which are expressed on most cells in the body. CD4 T cells bind class II MHC which are only expressed on specialized APCs. APCs primarily reside in 2 ° lymphoid tissue (lymph nodes, spleen) but can be found in most tissues. II. MHC Genetics Mouse MHC gene complex called H-2. Human MHC gene complex called HLA. MHC Molecules Mouse H-2 Human HLA Class I K,D,L A, B, C Class II I-A, I-E DR, DQ, DP Definitions: Alleles functional forms of the same genes. Heterozygous different allele at each locus. Homozygous same allele at each locus. Haplotype is the total set of MHC alleles present on one chromosome. For each MHC gene locus you have 2 copies which can be denoted by their allele classification. Most humans will be heterozygous and will have different alleles for each of the different HLA loci. (e.g. A2/A12, B17/B83, C3/C37, DR3/DR4 etc). Syngeneic identical at all MHC loci same allele on both chromosomes. (inbred mice or identical twins). Allogeneic --genetically different at MHC different alleles. Every person gets a chromosome from each biological parent which contains an MHC molecule at each locus.
    [Show full text]
  • Repertoire Selection from Data on the Mature T Cell Deriving Quantitative
    Deriving Quantitative Constraints on T Cell Selection from Data on the Mature T Cell Repertoire This information is current as Vincent Detours, Ramit Mehr and Alan S. Perelson of October 2, 2021. J Immunol 2000; 164:121-128; ; doi: 10.4049/jimmunol.164.1.121 http://www.jimmunol.org/content/164/1/121 Downloaded from References This article cites 75 articles, 24 of which you can access for free at: http://www.jimmunol.org/content/164/1/121.full#ref-list-1 Why The JI? Submit online. http://www.jimmunol.org/ • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average by guest on October 2, 2021 Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2000 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Deriving Quantitative Constraints on T Cell Selection from Data on the Mature T Cell Repertoire1 Vincent Detours,*†‡ Ramit Mehr,§ and Alan S. Perelson2* The T cell repertoire is shaped in the thymus through positive and negative selection. Thus, data about the mature repertoire may be used to infer information on how TCR generation and selection operate.
    [Show full text]
  • Thymic Nurse Cells Participate in Heterotypic
    Send Orders for Reprints to [email protected] 828 Current Molecular Medicine 2015, 15, 828-835 Thymic Nurse Cells Participate in Heterotypic Internalization and Repertoire Selection of Immature Thymocytes; Their Removal from the Thymus of Autoimmune Animals May be Important to Disease Etiology J.C. Guyden1, M. Martinez2, R.V.E. Chilukuri1, V. Reid3, F. Kelly4 and M.-O.D. Samms*,1 1Department of Biology, The City College of New York, New York, NY 10031, USA 2Department of Biology College of Arts and Sciences, Tuskegee University, Armstrong Hall, Room 107, 1200 West Montgomery Road, Tuskegee, AL 36088, USA 3The Hall Perrine Cancer Center, Department of Surgery, Mercy Medical Center Cedar Rapids, IA, Division of Surgical Oncology & Endocrine Surgery, The University of Iowa Hospitals & Clinics, 200 Hawkins Dr, Iowa City, IA 52242, USA 4Essential Health, St Mary’s Medical Center, 407 East 3rd Street, Duluth, MN 55805, USA M.-O.D. Samms Abstract: Thymic nurse cells (TNCs) are specialized epithelial cells that reside in the thymic cortex. The initial report of their discovery in 1980 showed TNCs to contain up to 200 thymocytes within specialized vacuoles in their cytoplasm. Much has been reported since that time to determine the function of this heterotypic internalization event that exists between TNCs and developing thymocytes. In this review, we discuss the literature reported that describes the internalization event and the role TNCs play during T cell development in the thymus as well as why these multicellular complexes may be important in inhibiting the development of autoimmune diseases. Keywords: Thymic nurse cells, internalization, MHC restriction, lupus erythromatosus.
    [Show full text]
  • Understanding the Immune System: How It Works
    Understanding the Immune System How It Works U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH National Institute of Allergy and Infectious Diseases National Cancer Institute Understanding the Immune System How It Works U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH National Institute of Allergy and Infectious Diseases National Cancer Institute NIH Publication No. 03-5423 September 2003 www.niaid.nih.gov www.nci.nih.gov Contents 1 Introduction 2 Self and Nonself 3 The Structure of the Immune System 7 Immune Cells and Their Products 19 Mounting an Immune Response 24 Immunity: Natural and Acquired 28 Disorders of the Immune System 34 Immunology and Transplants 36 Immunity and Cancer 39 The Immune System and the Nervous System 40 Frontiers in Immunology 45 Summary 47 Glossary Introduction he immune system is a network of Tcells, tissues*, and organs that work together to defend the body against attacks by “foreign” invaders. These are primarily microbes (germs)—tiny, infection-causing Bacteria: organisms such as bacteria, viruses, streptococci parasites, and fungi. Because the human body provides an ideal environment for many microbes, they try to break in. It is the immune system’s job to keep them out or, failing that, to seek out and destroy them. Virus: When the immune system hits the wrong herpes virus target or is crippled, however, it can unleash a torrent of diseases, including allergy, arthritis, or AIDS. The immune system is amazingly complex. It can recognize and remember millions of Parasite: different enemies, and it can produce schistosome secretions and cells to match up with and wipe out each one of them.
    [Show full text]
  • A Novel BCMA/CD3 Bispecific T-Cell Engager for the Treatment
    OPEN Leukemia (2017) 31, 1743–1751 www.nature.com/leu ORIGINAL ARTICLE A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo S Hipp1, Y-T Tai2,3, D Blanset4, P Deegen5, J Wahl5, O Thomas5, B Rattel5, PJ Adam1, KC Anderson2,3 and M Friedrich5 B-cell maturation antigen (BCMA) is a highly plasma cell-selective protein that is expressed on malignant plasma cells of multiple myeloma (MM) patients and therefore is an ideal target for T-cell redirecting therapies. We developed a bispecific T-cell engager (BiTE) targeting BCMA and CD3ε (BI 836909) and studied its therapeutic impacts on MM. BI 836909 induced selective lysis of BCMA- positive MM cells, activation of T cells, release of cytokines and T-cell proliferation; whereas BCMA-negative cells were not affected. Activity of BI 836909 was not influenced by the presence of bone marrow stromal cells, soluble BCMA or a proliferation-inducing ligand (APRIL). In ex vivo assays, BI 836909 induced potent autologous MM cell lysis in both, newly diagnosed and relapsed/ refractory patient samples. In mouse xenograft studies, BI 836909 induced tumor cell depletion in a subcutaneous NCI-H929 xenograft model and prolonged survival in an orthotopic L-363 xenograft model. In a cynomolgus monkey study, administration of BI 836909 led to depletion of BCMA-positive plasma cells in the bone marrow. Taken together, these results show that BI 836909 is a highly potent and efficacious approach to selectively deplete BCMA-positive MM cells and represents a novel immunotherapeutic for the treatment of MM.
    [Show full text]
  • Immunology 101
    Immunology 101 Justin Kline, M.D. Assistant Professor of Medicine Section of Hematology/Oncology Committee on Immunology University of Chicago Medicine Disclosures • I served as a consultant on Advisory Boards for Merck and Seattle Genetics. • I will discuss non-FDA-approved therapies for cancer 2 Outline • Innate and adaptive immune systems – brief intro • How immune responses against cancer are generated • Cancer antigens in the era of cancer exome sequencing • Dendritic cells • T cells • Cancer immune evasion • Cancer immunotherapies – brief intro 3 The immune system • Evolved to provide protection against invasive pathogens • Consists of a variety of cells and proteins whose purpose is to generate immune responses against micro-organisms • The immune system is “educated” to attack foreign invaders, but at the same time, leave healthy, self-tissues unharmed • The immune system can sometimes recognize and kill cancer cells • 2 main branches • Innate immune system – Initial responders • Adaptive immune system – Tailored attack 4 The immune system – a division of labor Innate immune system • Initial recognition of non-self (i.e. infection, cancer) • Comprised of cells (granulocytes, monocytes, dendritic cells and NK cells) and proteins (complement) • Recognizes non-self via receptors that “see” microbial structures (cell wall components, DNA, RNA) • Pattern recognition receptors (PRRs) • Necessary for priming adaptive immune responses 5 The immune system – a division of labor Adaptive immune system • Provides nearly unlimited diversity of receptors to protect the host from infection • B cells and T cells • Have unique receptors generated during development • B cells produce antibodies which help fight infection • T cells patrol for infected or cancerous cells • Recognize “foreign” or abnormal proteins on the cell surface • 100,000,000 unique T cells are present in all of us • Retains “memory” against infections and in some cases, cancer.
    [Show full text]
  • Regulatory T Cell Research
    Regulatory T cell research Unique kits for cell isolation Harmonized cell culture and expansion tools Convenient functional assay tools Germany/Austria/ Benelux France Nordics and Baltics South Korea Switzerland Miltenyi Biotec B.V. Miltenyi Biotec SAS Miltenyi Biotec Norden AB Miltenyi Biotec Korea Co., Ltd Reliable flow cytometry analysis Miltenyi Biotec GmbH Schipholweg 68 H 10 rue Mercoeur Scheelevägen 17 Arigi Bldg. 8F Friedrich-Ebert-Straße 68 2316 XE Leiden 75011 Paris, France 223 70 Lund 562 Nonhyeon-ro 51429 Bergisch Gladbach The Netherlands Phone +33 1 56 98 16 16 Sweden Gangnam-gu Germany [email protected] Fax +33 1 56 98 16 17 [email protected] Seoul 06136, South Korea Phone +49 2204 8306-0 Customer service [email protected] Customer service Sweden Phone +82 2 555 1988 Fax +49 2204 85197 The Netherlands Phone 0200-111 800 Fax +82 2 555 8890 [email protected] Phone 0800 4020120 Italy Fax 046-280 72 99 [email protected] Fax 0800 4020100 Miltenyi Biotec S.r.l. Customer service Denmark USA/Canada Customer service Belgium Via Persicetana, 2/D Phone 80 20 30 10 Spain Miltenyi Biotec Inc. Phone 0800 94016 40012 Calderara di Reno (BO) Fax +46 46 280 72 99 Miltenyi Biotec S.L. 2303 Lindbergh Street Fax 0800 99626 Italy Customer service C/Luis Buñuel 2 Auburn, CA 95602, USA Customer service Luxembourg Phone +39 051 6 460 411 Norway, Finland, Iceland, Ciudad de la Imagen Phone 800 FOR MACS Phone 800 24971 Fax +39 051 6 460 499 and Baltic countries 28223 Pozuelo de Alarcón (Madrid) Phone +1 530 888 8871 Fax 800 24984 [email protected] Phone +46 46 280 72 80 Spain Fax +1 877 591 1060 Fax +46 46 280 72 99 Phone +34 91 512 12 90 [email protected] China Japan Fax +34 91 512 12 91 Miltenyi Biotec Technology & Miltenyi Biotec K.K.
    [Show full text]
  • The Anatomy of T-Cell Activation and Tolerance Anna Mondino*T, Alexander Khoruts*, and Marc K
    Proc. Natl. Acad. Sci. USA Vol. 93, pp. 2245-2252, March 1996 Review The anatomy of T-cell activation and tolerance Anna Mondino*t, Alexander Khoruts*, and Marc K. Jenkins Department of Microbiology and the Center for Immunology, University of Minnesota Medical School, 420 Delaware Street S.E, Minneapolis, MN 55455 ABSTRACT The mammalian im- In recent years, it has become clear that TCR is specific for a self peptide-class I mune system must specifically recognize a full understanding of immune tolerance MHC complex) T cell that will exit the and eliminate foreign invaders but refrain cannot be achieved with reductionist in thymus and seed the secondary lymphoid from damaging the host. This task is vitro approaches that separate the individ- tissues (3, 4). In contrast, cortical CD4+ accomplished in part by the production of ual lymphocyte from its in vivo environ- CD8+ thymocytes that express TCRs that a large number of T lymphocytes, each ment. The in vivo immune response is a have no avidity for self peptide-MHC bearing a different antigen receptor to well-organized process that involves mul- complexes do not survive and die by an match the enormous variety of antigens tiple interactions of lymphocytes with each apoptotic mechanism. Cortical epithelial present in the microbial world. However, other, with bone-marrow-derived antigen- cells are essential for the process of pos- because antigen receptor diversity is gen- presenting cells (APCs), as well as with itive selection because they display the self erated by a random mechanism, the im- nonlymphoid cells and their products. The peptide-MHC complexes that are recog- mune system must tolerate the function of anatomic features that are designed to op- nized by CD4+ CD8+ thymocytes and also T lymphocytes that by chance express a timize immune tolerance toward innocuous provide essential differentiation factors self-reactive antigen receptor.
    [Show full text]
  • Vaccine Immunology Claire-Anne Siegrist
    2 Vaccine Immunology Claire-Anne Siegrist To generate vaccine-mediated protection is a complex chal- non–antigen-specifc responses possibly leading to allergy, lenge. Currently available vaccines have largely been devel- autoimmunity, or even premature death—are being raised. oped empirically, with little or no understanding of how they Certain “off-targets effects” of vaccines have also been recog- activate the immune system. Their early protective effcacy is nized and call for studies to quantify their impact and identify primarily conferred by the induction of antigen-specifc anti- the mechanisms at play. The objective of this chapter is to bodies (Box 2.1). However, there is more to antibody- extract from the complex and rapidly evolving feld of immu- mediated protection than the peak of vaccine-induced nology the main concepts that are useful to better address antibody titers. The quality of such antibodies (e.g., their these important questions. avidity, specifcity, or neutralizing capacity) has been identi- fed as a determining factor in effcacy. Long-term protection HOW DO VACCINES MEDIATE PROTECTION? requires the persistence of vaccine antibodies above protective thresholds and/or the maintenance of immune memory cells Vaccines protect by inducing effector mechanisms (cells or capable of rapid and effective reactivation with subsequent molecules) capable of rapidly controlling replicating patho- microbial exposure. The determinants of immune memory gens or inactivating their toxic components. Vaccine-induced induction, as well as the relative contribution of persisting immune effectors (Table 2.1) are essentially antibodies— antibodies and of immune memory to protection against spe- produced by B lymphocytes—capable of binding specifcally cifc diseases, are essential parameters of long-term vaccine to a toxin or a pathogen.2 Other potential effectors are cyto- effcacy.
    [Show full text]
  • HLA-Restricted, Processing- and Metabolism-Independent Pathway of Drug Recognition by Human Alpha Beta T Lymphocytes
    HLA-restricted, processing- and metabolism-independent pathway of drug recognition by human alpha beta T lymphocytes. M P Zanni, … , S Valitutti, W J Pichler J Clin Invest. 1998;102(8):1591-1598. https://doi.org/10.1172/JCI3544. Research Article T cell recognition of drugs is explained by the hapten-carrier model, implying covalent binding of chemically reactive drugs to carrier proteins. However, most drugs are nonreactive and their recognition by T cells is unclear. We generated T cell clones from allergic individuals specific to sulfamethoxazole, lidocaine (nonreactive drugs), and cef-triaxone (per se reactive beta-lactam antibiotic) and compared the increase of intracellular free calcium concentration ([Ca2+]i) and the kinetics of T cell receptor (TCR) downregulation of these clones by drug-specific stimulations. All drugs tested induced an MHC-restricted, dose- and antigen-presenting cell (APC)-dependent TCR downregulation on specific CD4(+) and CD8(+) T cell clones. Chemically nonreactive drugs elicited an immediate and sustained [Ca2+]i increase and a rapid TCR downregulation, but only when these drugs were added in solution to APC and clone. In contrast, the chemically reactive hapten ceftriaxone added in solution needed > 6 h to induce TCR downregulation. When APC were preincubated with ceftriaxone, a rapid downregulation of the TCR and cytokine secretion was observed, suggesting a stable presentation of a covalently modified peptide. Our data demonstrate two distinct pathways of drug presentation to activated specific T cells. The per se reactive ceftriaxone is presented after covalent binding to carrier peptides. Nonreactive drugs can be recognized by specific alphabeta+ T cells via a nonconventional presentation pathway based on a labile binding […] Find the latest version: https://jci.me/3544/pdf HLA-restricted, Processing- and Metabolism-independent Pathway of Drug Recognition by Human ab T Lymphocytes Martin P.
    [Show full text]
  • Maxpar Human Helper T-Cell
    PRD013-201318 Rev. 7 PRODUCT INFORMATION SHEET Maxpar Human Helper T Cell Phenotyping Panel Kit, 15 Marker—25 Tests Catalog: 201318 Storage: Package size: 25 tests • Antibodies, buffers, and water: 4 °C. Do not freeze. • Cell-ID Intercalator-Ir: –20 °C. Contents: Target Clone Metal Target Clone Metal • Maxpar® Cell Staining Buffer (500 mL) CD196/CCR6 G034E3 141Pr CD161 HP-3G10 159Tb • Maxpar Fix and Perm Buffer (25 mL) CD195/CCR5 NP-6G4 144Nd CD45RO UCHL1 165Ho • Maxpar Water (500 mL) CD8 RPA-T8 146Nd CD25 2A3 169Tm • Cell-IDTM Intercalator-Ir (125 µM; 25 µL) CD278/ICOS C398.4A 151Eu CD185/CXCR5 RF8B2 171Yb • Maxpar antibodies (see table for panel)* CD45RA HI100 153Eu CD4 SK3 174Yb CD3 UCHT1 154Sm CD279/PD-1 EH12.2H7 175Lu * The antibodies are provided in individual tubes, not a pre-mixed cocktail. CD183/CXCR3 G025H7 156Gd CD127 A019D5 176Yb CD194/CCR4 L291H4 158Gd Technical Information Description: The Maxpar Human Helper T Cell Phenotyping Panel Kit is for the identification and phenotyping of human CD4+ helper T cell subsets, including T helper 1 (TH1), TH2, TH17, TH22, T follicular helper (TFH), and T regulatory (TREG). Differentiation of CD4+ T cells into functionally distinct helper T subsets is essential for normal immunoregulation. These subsets are specified by extrinsic and intrinsic cues, and the resultant cell populations acquire stable phenotypes defined by the expression of signature cytokines, master regulator transcription factors, and characteristic cell surface phenotypes. Originally, CD4+ T cells were viewed as having only two major fates: 1) TH1 cells, which express T-bet and selectively produce interferon IFNγ and 2) TH2 cells, which express Gata3 and produce interleukin 4 (IL-4).
    [Show full text]